The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Amryt Pharma plc | Common | 03217L106 | 38,911,731 | 2,668,843 | SH | SOLE | 2,668,843 | 0 | 0 | |||
Dyne Therapeutics, Inc. | Common | 26818M108 | 57,039,011 | 4,951,303 | SH | SOLE | 4,951,303 | 0 | 0 | |||
Entrada Therapeutics, Inc. | Common | 29384C108 | 64,173,868 | 4,425,784 | SH | SOLE | 4,425,784 | 0 | 0 | |||
Harpoon Therapeutics, Inc. | Common | 41358P106 | 2,329,753 | 3,131,388 | SH | SOLE | 3,131,388 | 0 | 0 | |||
iTeos Therapeutics, Inc. | Common | 46565G104 | 37,274,864 | 2,738,785 | SH | SOLE | 2,738,785 | 0 | 0 | |||
Oncorus, Inc. | Common | 68236R103 | 980,216 | 2,849,464 | SH | SOLE | 2,849,464 | 0 | 0 | |||
Repare Therapeutics, Inc. | Common | 760273102 | 22,067,538 | 2,242,636 | SH | SOLE | 2,242,636 | 0 | 0 | |||
TCR2 Therapeutics, Inc. | Common | 87808K106 | 6,076,298 | 4,050,865 | SH | SOLE | 4,050,865 | 0 | 0 | |||
Werewolf Therapeutics, Inc. | Common | 95075A107 | 11,138,847 | 4,284,172 | SH | SOLE | 4,284,172 | 0 | 0 |